Tuesday, September 22, 2020

Global #CBD/#Hemp Industry Snapshot (OTC: $CSUI) (OTC: $MJNA) (CSE: $TGIF.C) (OTCQX: $TGIFF), (TSXV: $KHRN.V) (OTCQX: $KHRNF)

 Global #CBD/#Hemp Industry Snapshot (OTC: $CSUI) (OTC: $MJNA) (CSE: $TGIF.C) (OTCQX: $TGIFF), (TSXV: $KHRN.V) (OTCQX: $KHRNF); @SuisseCorp @1933Industries @MJNA_INC @KhironLife

 

How Distribution Platforms Are Growing the Sector

 

Point Roberts WA, Delta, BC –September 22, 2020 - Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a special report on the continued growth of the global CBD/hemp industry as additional international markets come into play and how smart companies hedging for the future are putting their focus into globalized distribution systems.

 

Read this article, featuring CSUI in full at https://www.investorideas.com/news/2020/cannabis/09221CSUI-MJNA-TGIF-KHRN.asp

 

As we see more global acceptance of the hemp/CBD industry, whether in the form of new import/export regulations coming into play in South America, potential markets opening up South East Asia, Japan and South Korea or larger companies like Amazon being more acceptant of hemp/CBD products, the CBD industry is going global faster than many anticipated, especially in the midst of a global pandemic. That being said, one of the most significant drivers of this industry today is the renewed focus on health and wellness and immune boosting products that we’ve seen ramp up due to the COVID-19 pandemic.

 


One company based out of Switzerland, Cannabis Suisse Corp. (OTC: CSUI), a fully-licensed Swiss cannabis cultivation and distribution company for recreational tobacco products and medical CBD oils, recently announced its own online expansion plans including the upcoming launch of a new brand on Amazon.

 

Сannabis Suisse Corp. is developing its own line of products including hemp oil, hemp protein, hemp gummies and hemp hearts with all the appropriate certificates and licenses, for sale on Amazon.

 

This news follows a recent announcement for online distribution of its cannabis and CBD products with uWeed from their retail outlets and online store (www.uweed.ch).

 

The expansion into online sales of hemp gives the company, which is headquartered in Switzerland, wider access and inroads into US markets as the legal environment for CBD products evolves. 

 

Mr. Alain Parrik, COO & Director said, “Amazon is an important distribution outlet for us as we ramp up for expansion across multiple online retail platforms. Introducing a new line of hemp products paves the wave for additional products in the future.”

 

Cannabis Suisse Corp. will be in compliance with Amazon rules and respects their position that CBD is currently banned on Amazon but hemp products are not.

The Company, as a registered manufacturer of both products will continue to use flowers with the highest concentration of CBD. For the new Amazon product line, oil will be squeezed from the seeds allowing Cannabis Suisse to use the whole plant in its production and benefit from it.

 

The Company grows high quality, organic cannabis with sustainable, all-natural principles. Cannabis Suisse products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product.



Source: Brightfield Group Quarterly CBD Consumer Survey, Q2, 2020, Sample size = 5,000

 

Looking more to domestic markets, 1933 Industries Inc. (CSE: TGIF) (OTCQX: TGIFF), a vertically-integrated cannabis consumer packaged goods company with a diverse portfolio of consumer-driven brands, recently announced that it has set up distribution of its Canna Hemp™ line of wellness products in conjunction with CBD Plus, the largest and most trusted supplier of CBD products across the United States.

 

The Company reports that its wholly-owned subsidiary, Infused MFG, signed a Master Services and Supply Agreement with MCV Enterprises LLC, an Oklahoma company doing business as CBD Plus and CBD Plus USA, for the marketing and sale of Canna Hemp™ products in CBD Plus corporate-owned and franchisee brick and mortar retail stores. The one-year Agreement includes a 45-day trial period, effective immediately.

 

CBD Plus is focused in the Midwest and Southern US, with over 120 locations and growing - in Texas, Oklahoma, Kansas, Arkansas, Tennessee, Georgia, Florida, North Carolina, and Maryland. The partnership with CBD Plus is another important step for the Company as it builds the Canna Hemp™ line as a leading brand in the US CBD market. According to the latest outlook by the Brightfield Group, hemp-based CBD US sales will reach $12.4 billion by 2023 and $16.8 billion by 2025.

 

Mr. Eugene Ruiz, President of 1933 Industries said, "CBD Plus is a well-respected source of safe, legal and affordable CBD products that meet the highest standards in the industry. We are pleased that our Canna Hemp™ line meets and exceeds those high standards. We look forward to collaborating with CBD Plus to increase awareness and education regarding the benefits and value of CBD in our everyday lives."

 

"CBD Plus and its family of franchisees is proud to announce its relationship with 1933 industries", said Mr. Charles V. Reynolds III, CEO of CBD Plus. "We look forward to introducing Canna Hemp™ products to our entire customer base nationwide. Quality Assurance and Cannabis Education have always been cornerstones of the CBD Plus USA mission, and we are excited to partner with a brand such as Canna Hemp™ that shares those values. We remain committed to helping educate the public on all of the benefits and uses of quality CBD, and we believe this relationship aligns with our goals."

 

CBD Plus has been committed to improving the lives of communities since 2017, and has now grown into a trusted source of CBD products in the US. Founded on the cornerstone of empowering customers to live their best lives, CBD Plus has become an authoritative advocate for CBD, and a dedicated educator of the benefits of CBD oil. CBD Plus offers a variety of self-care and lifestyle products with CBD that exceeds the industry standard of quality, producing carefully extracted, pesticide-free, and non-GMO products.

 

Looking back to the international market, Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, recently announced that its subsidiary HempMeds® Brasil had its best revenue month ever in Company history in August 2020.

 

“Since 2015, HempMeds® Brasil has sold more than 80,000 units of cannabidiol (CBD) to Brazilian citizens,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “We are proud to be the recipients of the first permits to import CBD into Brazil and we have been able to become industry leaders there.”

 

“Our Company was formed and is led by Brazilians – we care immensely about providing people here with affordable, high-quality CBD products that are legal and scientifically-proven,” said HempMeds® Co-CEO, Caroline Heinz. “We have showcased to citizens even despite a global pandemic and a very poor currency exchange rate, we have been able to increase our sales and make our products affordable for the struggling economy through adjusting our prices and offering payment plans.”

 

Before becoming Co-CEO of HempMeds®’ operations, Heinz served as Vice President of HempMeds® Brasil. She joined the Company in 2014 and helped pass legislation to get the Brazilian government to subsidize CBD for several indications. She was also able to establish two HempMeds® Brasil offices and create a network of Brazilian doctors and medical professionals.

 

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, recently announced that it has entered into an exclusive distribution agreement with Rappi SAS, the leading Latin American last-mile multi-vertical platform that is backed with a USD 1 billion investment from Softbank Group Corp., and Softbank Vision Fund.  The expansive agreement comprises a 6-month exclusive distribution partnership between Rappi and Khiron to introduce and distribute the Company's CPG product portfolio across Latin America through the Rappi platform, starting with KuidaTM, the Company's branded CBD skincare product line, with the potential to build on the partnership over time.

 

Beyond a standard vendor agreement, this expanded partnership introduces the Company's CBD-based Wellbeing products to millions of Rappi users across Latin America through its sophisticated technology and advanced customer-centric marketing strategies. With the Kuida store already launched on Rappi in May 2020 for the Colombian market, distribution will be expanded to Uruguay and Costa Rica, where Kuida has been recently approved. The Company also intends to introduce its product line through Rappi's fast growing consumer base to countries such as Brazil, Mexico, Ecuador and Chile, subject to regulatory approvals.

Colombia's Rappi is the market leading multi-vertical application in Latin America with a presence in Brazil, Colombia, Mexico, Argentina, Chile, Ecuador, Costa Rica, Uruguay and Peru.

 

Through its platform, customers buy products and services and receive home delivery across multiple categories, including, medical, health, grocery, restaurants, pharmacies, beverage and professional services among others. In addition, the application has a virtual wallet, RappiPayTM, where users can make P2P transfers and payments.  Rappi has an average of more than 10 million active users monthly, according to research firm Apptopia, providing deliveries for almost 100,000 businesses in LatAm, including over 13 million deliveries in Colombia alone.

 

"Rappi is the delivery brand that everyone in Latin America knows and uses daily. The partnership with Rappi reduces our product launch and logistics costs and transforms our availability and exposure to millions of customers across the region. Rappi is the last-mile delivery brand that will help us bring Khiron product to more customers than ever before. We are proud to establish this first-of-its-kind partnership between these two companies, which are both industry leaders in LatAm, and were both founded by Colombians," comments Alvaro Torres, Khiron CEO and director.

 

"As the market for consumer cannabis products and services globalizes it is a natural fit for us to partner with Khiron to meet our app users´ needs. Like us, they are a recognized leader in the region, and an innovator in bringing quality products to market, "comments Simon Borrero, Rappi SAS CEO.

 

As the CBD/hemp space continues to gain global momentum, new distribution platforms and models as well as a heavy focus on product quality, consistency and efficacy will become more and more paramount for companies looking to be a global player and make no mistake, this is a global play. With companies like Amazon now also entering into the space, the level of competition has risen dramatically and investors should now be looking at the distribution and supply chain of any CBD/hemp company first and foremost as this looks to be an impactful factor moving forward.  

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring CSUI is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

 



 

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

 

Buy a cannabis guest post on Investorideas.com

 

 

 

 

 

 

 



 

Monday, September 21, 2020

Investorideas.com - Viridian Cannabis Deal Tracker Chart Of The Week

Investorideas.com - Viridian Cannabis Deal Tracker Chart Of The Week

Join our Investor Club https://www.investorideas.com/membership/

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 470 (OTCQB: $CTABF) (OTC: $CSUI), (OTCQX: $AVCNF), (TSXV: $PCLO.V) (OTCQX: $PCLOF)

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 470 (OTCQB: $CTABF) (OTC: $CSUI), (OTCQX: $AVCNF), (TSXV: $PCLO.V) (OTCQX: $PCLOF)

 

Today’s podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland

 


Delta, Kelowna, BC, September 21, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/092120-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/09211CTABF-CSUI-AVCNF-PCLO-PCLOF.asp

 

Hear the investor ideas potcast on Spotify

 

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

Today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

 

In today’s podcast we look at a few public company announcements.

 

Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announced that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038.

 

Larry Latowsky, CEO of Canntab said "this is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.

 

The patent granted is for Canntab's bi-layer or multi-layer tablets consisting of both Instant Release ("IR") and Extended Release ('XR") formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.

 

Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a 3rd party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations making it the clear delivery choice for doctors, patients or the average consumer.

 

"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications" continued Latowsky.

 

In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.

 

This issued patent covers Canntab's modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.   

 

Canntab has filed applications for 13 patents in Canada and the United States that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis. These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended release tablets, oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.

 

Cannabis Suisse Corp. (OTC:CSUI), a fully licensed Swiss cannabis cultivation and distribution company for recreational tobacco products and medical CBD oils, announced the company’s online expansion plans including the upcoming launch of a new brand on Amazon.

 

Сannabis Suisse Corp. is developing its own line of products including hemp oil, hemp protein, hemp gummies and hemp hearts with all the appropriate certificates and licenses for sale on Amazon.

 

This news follows a recent announcement for online distribution of its cannabis and CBD products with uWeed from their retail outlets and online store (www.uweed.ch).

The expansion into online sales of hemp gives the company headquartered in Switzerland, wider access and inroads into the US markets and the legal environment for CBD products evolves.

 

Mr. Alain Parrik, COO & Director said, " Amazon, is an important distribution outlet for us as we ramp up for expansion across multiple online retail platforms. Introducing a new line of hemp products paves the wave for additional products in the future."

 

Cannabis Suisse Corp. will be in compliance with Amazon rules and respects their position that CBD is currently banned on Amazon but hemp products are not.

 

The Company, as a registered manufacturer of both products, will continue to use flowers with the highest concentration of CBD. For the new Amazon product line, oil will be squeezed from the seeds allowing Cannabis Suisse to use the whole plant in its production and benefit from it.

 

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that its advanced RHO Phyto Rapid Act Sprays are now officially available nationwide in Canada on the Medical Cannabis by Shoppers portal, as well as through the Medical Cannabis Real-World Evidence Study at the University Health Network.

 

Avicanna's RHO Phyto product line is now commercially available after years of research and development through collaborations with world class academic and clinical organizations. The development of RHO Phyto products has focused on the key properties in drug development that health care providers seek when recommending a medical product to their patients such as formulation stability for consistent dosing, enhanced absorption and a range of onset times.

 

The Rapid Act Spray is a sublingual spray and is among the second set of Avicanna's RHO Phyto products available for purchase through Shoppers. The sublingual sprays bypass first-pass metabolism and are quickly absorbed in the mucosal lining under the tongue. The RHO Phyto Rapid Act Spray provides an alternative delivery form to the RHO Phyto Micro Drops (also available for sale through Shoppers) which are absorbed through the oral route. The RHO Phyto Rapid Act Sprays have been formulated with specific ingredients that enhance absorption and the onset time of cannabinoids across the mucous membrane beneath the tongue. The lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40 (w/w) THC to CBD ratios.

 

Dr. Justin Grant, Avicanna's Executive Vice President of Scientific Affairs, commented, "The RHO Phyto Rapid Act Sprays are designed for faster onset and can be used in acute conditions where patients seek faster relief. The sublingual sprays can also be used to supplement slower and longer acting products, such as the RHO Phyto Micro Drop, when occasional higher doses may be required. Sublingual administration provides an alternative to the potentially harmful effects of consuming inhalation products."

 

In August 2020, Avicanna launched its blood orange flavoured RHO Phyto Micro Drop 2:50 CBD and Micro Drop 5:20 CBD. In the coming months, Avicanna will be launching its much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured at MediPharm Labs Inc, a Good Manufacturing Practices ("GMP") certified facility. In addition to strict GMP manufacturing, all RHO Phyto products undergo GMP-level analytical testing by Sigma Analytical Services Inc. and use blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.

 

Detailed guidelines outlining dosing and titration for Health Care Practitioners ("HCPs") and patients is available on the RHO Phyto website at www.rhophyto.com. In addition, the Avicanna Academy includes additional product information for patients, frequently asked questions, and a recording of Avicanna's 3rd annual symposium which was hosted virtually in partnership with Shoppers on July 21, 2020. For more information visit https://www.avicanna.com/the-avicanna-academy/.

 

The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as My Cannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care to patients and providing education on the considerations and potential benefits that cannabis has to offer for medical use. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/.

 

PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced today that it has begun sales and distribution of an expanded range of medicinal-grade cannabis extracts cultivated and produced at its Rionegro facilities.

 

PharmaCielo has been enabled to address customer product inquiries based on technical experience to date combined with increased laboratory and processing capabilities and allowing it to begin commercial production of a significantly expanded range of extract products that began with CBD Isolate and now includes Broad Spectrum Oil, CBD Broad Spectrum Distillate, Water Soluble CBDCBD Tincture, CBD Distillate Tincture, Full Spectrum Oil Tincture, THC:CBD Formulations and THC Distillate.

 

"The ability to offer a wide range of bulk products which vary in cannabinoids combination, potency and terpenes content is highly sought-after in the medicinal and wellness sector, as some specific products deliver specific benefits, while others can deliver a full suite of cannabinoid benefits, known as the entourage effect," said David Attard, CEO of PharmaCielo Ltd.  "With our different formulations we are also able to provide customers with the flexibility to formulate their final product according to the individual health and drug delivery system needs."

 

Each of PharmaCielo's extracts are derived from unique and proprietary cultivars developed by the Company's horticultural research experts, optimized for year-round Colombian open-field cultivation, with each extract profile reflecting the unique nature of the cultivar.  By example, Broad Spectrum Oil is carefully purified to yield a beautiful amber coloured cannabinoid-rich extract that features multiple cannabinoids, including Cannabidiol (CBD), Cannabidiolic Acid (CBDA), Cannabigerol (CBG), Cannabichromene (CBC), Cannabidivarin (CBDV) and complemented by a range of naturally occurring terpenes including Pinene, Limonene, Linalool, and Myrceneas as part of its attributes.

 

The expansion of PharmaCielo's product portfolio comes on the heels of a multi-year investment in its processing and extraction capabilities. The Company has begun processing part of its formulations at the expanded facility and is in the position to meet customer demand for commercial volumes at consistent high-quality, purity and potency levels required by healthcare standards.

 

"As we developed the new product range, based on customer and prospect demand, our team placed a greater emphasis on ensuring we added Water Soluble CBD extract to the mix. The development of this product in particular, will enable PharmaCielo to explore integration opportunities with major players in the health-oriented beverage and topical products segments of the market, which have expressed interest in CBD additives," added Attard.

 

The Company has begun to accept orders for initial shipments of the new products in the balance of 2020, with continuing production capacity and shipments volumes increasing into 2021. The portfolio of extract products available in commercial volumes appropriate to the global market is expanding on a continuing basis with future additional product introductions expected.  Individual product profiles and pricing are available through sales@pharmacielo.com.

 


Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Cannabis Suisse Corp. (OTC: CSUI ),is a paid featured company on Investorideas.com  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

 

Cannabis Stock News: Cannabis Suisse Corp. (OTC: $CSUI) Expansion Plans for Online Sales, Adding to CBD product lines with New Hemp Brands @SuisseCorp

 

Cannabis Stock News: Cannabis Suisse Corp. (OTC: $CSUI) Expansion Plans for Online Sales, Adding to CBD product lines with New Hemp Brands @SuisseCorp

 

Company plans to expand online sales with retail giant Amazon ( $AMZN) 

 


DIETIKON, SWITZERLAND - Cannabis Suisse Corp. (OTC: CSUI), a fully licensed Swiss cannabis cultivation and distribution company for recreational tobacco products and medical CBD oils, announces online expansion plans including the upcoming launch of a new brand on Amazon.

 

Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/09211Expansion-Plans.asp

 

Сannabis Suisse Corp. is developing its own line of products including hemp oil, hemp protein, hemp gummies and hemp hearts with all the appropriate certificates and licenses, for sale on Amazon.

 

This news follows a recent announcement for online distribution of its cannabis and CBD products with uWeed from their retail outlets and online store (www.uweed.ch).

 

The  expansion into online sales of hemp gives the company, which is headquartered in Switzerland, wider access and inroads into US markets as the legal environment for CBD products evolves. 

 

Mr. Alain Parrik, COO & Director said, “Amazon is an important distribution outlet for us as we ramp up for expansion across multiple online retail platforms. Introducing a new line of hemp products paves the wave for additional products in the future.”

 

Cannabis Suisse Corp. will be in compliance with Amazon rules and respects their position that CBD is currently banned on Amazon but hemp products are not.

The Company, as a registered manufacturer of both products will continue to use flowers with the highest concentration of CBD. For the new Amazon product line, oil will be squeezed from the seeds allowing Cannabis Suisse to use the whole plant in its production and benefit from it.

 



Source: Brightfield Group Quarterly CBD Consumer Survey, Q2, 2020, Sample size = 5,000

Price Compression

 

 

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a fully licensed cannabis cultivation and distribution company in

Switzerland, for recreational tobacco products and medical CBD oils. The Company’s facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company’s products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

 

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.

This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

 

CONTACT:

Alain Parrik

Cannabis Suisse Corp.

+41445865314

alain.parrik@cannabissuisse.biz

 

SOURCE: Cannabis Suisse Corp

 

Cannabis Suisse (OTC: CSUI) is a featured Cannabis stock on Investorideas.com

 

Visit profile page

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure : Cannabis Suisse Corp. (OTC: CSUI) is a paid monthly cannabis company on Investorideas.com ( five thousand per month) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

 



 

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

 

Buy a cannabis guest post on Investorideas.com

 

 

Friday, September 18, 2020

Investorideas.com - Cannabis Stock News: The Valens Company (TSX: VLNS) (OTCQX: VLNCF) Manufactures Record Number of Product SKUs in the Third Quarter of Fiscal 2020

Investorideas.com - Cannabis Stock News: The Valens Company (TSX: VLNS) (OTCQX: VLNCF) Manufactures Record Number of Product SKUs in the Third Quarter of Fiscal 2020

#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp

 

#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp

 

 


DIETIKON, SWITZERLAND, September 18, 2020  - ( Investorideas.com newswire) – cannabis stock news - Cannabis Suisse (OTC: CSUI),recently reported a new service to the European market, Your Cannabis Grow, an innovative service which allows customers from Europe to grow their own cannabis seedling in one of Cannabis Suisse's indoor farms located in Switzerland.

 

Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/09181Your-Cannabis-Grow-European-Market.asp

 

This is an ethical, transparent and sustainable way to source the product containing essential CBD and EU sanctioned levels of THC - individually cultivated straight from the farm. Cannabis Suisse experts will monitor the entire cultivation process daily.

 

Customers can choose from an array of different cannabis strains. All the customers will be provided with a live video where they can watch the growth of the plants from the first seeding till the final harvest. The entire growth cycle of a cannabis plant is approximately 8-10 weeks, drying time is between 7-13 days. After being harvested, the THC level within the weed needs to be adjusted to meet the legal criteria of the country where the customer resides, then customers can have their weed shipped directly to their home. Harvest result is usually between 20 and 35 gr. per plant. On site, the plants are taken care of by Cannabis Suisse's master growers that are also involved in manufacturing of all the other products.

 

The price of 120 CHF includes all these services. Cannabis Suisse clients get a clone, a nameplate, a weekly photo of the plant, a certificate of the plant owner, photos of their drying plate, and as a result flowerheads shipped from the farm in anonymous packages.

 

The product can be ordered from the special website of the Company and from selected resellers. Cannabis Suisse Corp. also plans to sell it via a network of kiosks where customers can buy a plastic card already containing login and password data for the website. The intention is to do it especially in those type of kiosks that identify themselves as tobacco shops. Buying a card, customers are always sure that there is free space available at the farm.

 

In connection with the expansion of its services, Cannabis Suisse Corp. announces many special offers for its customers. There is giving out of 10 plants only for the subscribing to the Company's newsletters. As well ordering three plants at once, a buyer will receive the fourth one as a gift. Cannabis Suisse Corp. also offers open days. On selected days, the growers will be happy to welcome their customers personally at the facility.

 

Your Cannabis Grow is a hassle-free way to grow your own weed, there are many benefits and saving money is not the only one. Growing own cannabis plant has never been easier if the plant is in the hands of Cannabis Suisse's master growers. Cannabis Suisse has a top tier indoor farm that has no contaminants, customers' plants will be cared the same way as the rest of the products and receive the optimal conditions to grow and flourish. Growing own hemp is tricky even if it is grown only during the summer when there is not any need for special equipment.

 

Your Cannabis Grow is a service for everyone, but savvy customers that are well-versed in the different kinds of strains and already know what they prefer for regular consumption are going to see this service as an essential one. For someone who is experimenting, looking for new flavors or maybe new to cannabis consumption, Your Cannabis Grow might not be a commitment that is worth taking just yet. However, once a client has found that special strain, Your Cannabis Grow is a certain way to make sure that the strain is always in stock and even cheaper than ready-made products.

 

At the moment, a customer can choose from 6 different cannabis strains that give different aroma, taste and experiences. They are V1, Harlequin, White Alpine, Limoncello, Orange Alpine, Strawberry. This a great selection at launch and is going to be expanded and improved in the future.

 

Growing medical marijuana is legal in some European countries, but in Switzerland it is allowed to grow and sell cannabis for recreational or commercial use. It makes Switzerland unique and gives some interesting benefits for companies such as Cannabis Suisse Corp. Cannabis Suisse is using this opportunity to create a new market while also benefiting customers with a chance to own a legal cannabis farm plant that definitely has more benefits than having one in a back yard.

 

Cannabis Suisse Corp. is a forward-looking company and understands that consistent quality, trust and community creates a strong brand. The Company creates innovate products that people need and want to buy. Your Cannabis Grow is a service that is hopefully going to create a community that will trust in Cannabis Suisse future products and believe them to be worth sharing and supporting.

 

The release of Your Cannabis Grow is a new step for Cannabis Suisse Corp., while being extremely beneficial to customers. The service requires a time investment, but the outcome and saving are definitely worth the waiting. The service will evolve in the future and could even become an industry standard.

 

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

 

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

 

CONTACT:

Alain Parrik

Cannabis Suisse Corp.

+41445865314

alain.parrik@cannabissuisse.biz

 

SOURCE: Cannabis Suisse Corp

 

Cannabis Suisse (OTC: CSUI) is a featured Cannabis stock on Investorideas.com

 

Visit profile page

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure : Cannabis Suisse Corp. (OTC: CSUI) is a paid monthly cannabis company on Investorideas.com ( five thousand per month) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

 



 

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

 

Buy a cannabis guest post on Investorideas.com